Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Jose Antonio Gastelum
Jose Antonio Gastelum

Tyra Biosciences pursues new treatment strategies for urologic cancers

Tyra Biosciences pursues new treatment strategies for urologic cancers
Tyra Biosciences targets new cancer therapies

Tyra Biosciences is intensifying efforts to advance novel treatment approaches for individuals living with urologic cancers, including IR-NMIBC and LG-UTUC.

The company announced its intention to connect with urologists, oncologists, researchers, and patient advocates across the bladder cancer community, aiming to drive research and clinical progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Bitcoin mining is getting greener, but the debate isn't over
  • By Anastasiia Chabaniuk
  • 9 hours ago
Bitcoin mining is getting greener, but the debate isn't over
Editors' Picks
Asia's largest IPO: How CXMT became China's most valuable company
  • By Mikhail Vnuchkov
  • 13 hours ago
Asia's largest IPO: How CXMT became China's most valuable company
Editors' Picks
Global fintech in 2026: Three trends that matter
  • By Pavlo Kot
  • Yesterday
Global fintech in 2026: Three trends that matter
Editors' Picks
All Editors' Top Picks

Latest Tyra News

Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
  • By Eugene Komchuk
  • 24.07.2026
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
Companies
#Tyra
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC
  • By Andreas Kristo
  • 14.05.2026
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC
Companies
#Tyra
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
  • By Oleg Tkachenko
  • 05.05.2026
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
Companies
#Tyra
All Tyra News
  • Anastasiia Chabaniuk
  • 9 hours ago
Bitcoin mining is getting greener, but the debate isn't over
  • Mikhail Vnuchkov
  • 13 hours ago
Asia's largest IPO: How CXMT became China's most valuable company
  • Pavlo Kot
  • Yesterday
Global fintech in 2026: Three trends that matter
  • Pavlo Kot
  • 25.07.2026
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
  • Andrey Mastykin
  • 25.07.2026
Hunting crypto owners: Why criminals have gone offline
  • Mikhail Vnuchkov
  • 28 min ago
Andy Constan: Strategy benefited from high-priced share sales and $15–20 billion debt at par
  • Daria Chernytska
  • 43 min ago
Bitcoin trading below previous levels prompts investor interest, Quinten Francois notes
  • Elena Nikulina
  • 48 min ago
Luke Gromen: U.S. labor force and bond yields diverge since 2000
  • Yaroslav Dmytrenko
  • 58 min ago
Solana DAT is priced well below asset value, Ran Neuner notes
  • Hanna Syniavska
  • 1 hour ago
Laura Shin: ARK, AI capex, China’s open-weight ban and BitMEX shutdowns discussed on Bits + Bips
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Olga Shendetskaya
  • 8 hours ago
Treasury yields ease as investors turn to the Fed
Treasury yields ease as investors turn to the Fed
  • Hanna Syniavska
  • 10 hours ago
U.S. stock futures rally as oil prices retreat
U.S. stock futures rally as oil prices retreat
  • Olga Shendetskaya
  • 11 hours ago
CME Group launches futures on 55 major U.S. stocks
CME Group launches futures on 55 major U.S. stocks
  • Ivan Andriyenko
  • 13 hours ago
Nvidia considers $250 billion support for OpenAI project
Nvidia considers $250 billion support for OpenAI project
  • Hanna Syniavska
  • 14 hours ago
Brent falls below $90 as Middle East tensions ease
Brent falls below $90 as Middle East tensions ease
Live News
  • Anton Kharitonov
  • Now
Alphabet remains under pressure as AI investment concerns overshadow strong cloud growth
  • Anton Kharitonov
  • Now
Microsoft faces key earnings test as AI investment debate intensifies
  • Anton Kharitonov
  • Now
Apple approaches earnings as resilient momentum keeps shares near record highs
  • Mykhailo Ihnatenko
  • Now
Snowflake keeps bullish momentum intact above $270
  • Mykhailo Ihnatenko
  • Now
AMD stock seeks $565 as UBS lifts price target to $730
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR